ArticleJournal of clinical microbiology2000
Evaluation of performance of the Gen-Probe human immunodeficiency virus type 1 viral load assay using primary subtype A, C, and D isolates from Kenya.
Article in Journal of clinical microbiology, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 88 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
88 citing papers in PubMed, 140 citations in OpenAlex.
- Maternal Highly Active Antiretroviral Therapy Reduces Vertical Cytomegalovirus Transmission But Does Not Reduce Breast Milk Cytomegalovirus Levels.AIDS research and human retroviruses · 2017Trial
- Comparison of developmental milestone attainment in early treated HIV-infected infants versus HIV-unexposed infants: a prospective cohort study.BMC pediatrics · 2017Trial
- Nevirapine Resistance in Previously Nevirapine-Unexposed HIV-1-Infected Kenyan Infants Initiating Early Antiretroviral Therapy.AIDS research and human retroviruses · 2015Trial
- Correlates of age at attainment of developmental milestones in HIV-infected infants receiving early antiretroviral therapy.The Pediatric infectious disease journal · 2015Trial
- Compartmentalized cytomegalovirus replication and transmission in the setting of maternal HIV-1 infection.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2014Trial
- Valacyclovir suppressive therapy reduces plasma and breast milk HIV-1 RNA levels during pregnancy and postpartum: a randomized trial.The Journal of infectious diseases · 2012Trial
- Effects of valacyclovir on markers of disease progression in postpartum women co-infected with HIV-1 and herpes simplex virus-2.PloS one · 2012Trial
- HBV lamivudine resistance among hepatitis B and HIV coinfected patients starting lamivudine, stavudine and nevirapine in Kenya.Journal of viral hepatitis · 2011Trial
- A randomized controlled trial comparing the effects of counseling and alarm device on HAART adherence and virologic outcomes.PLoS medicine · 2011Trial
- Prevalence and correlates of helminth co-infection in Kenyan HIV-1 infected adults.PLoS neglected tropical diseases · 2010Trial
- Lower risk of resistance after short-course HAART compared with zidovudine/single-dose nevirapine used for prevention of HIV-1 mother-to-child transmission.Journal of acquired immune deficiency syndromes (1999) · 2009Trial
- Albendazole treatment of HIV-1 and helminth co-infection: a randomized, double-blind, placebo-controlled trial.AIDS (London, England) · 2008Trial
- HIV-1 persists in breast milk cells despite antiretroviral treatment to prevent mother-to-child transmission.AIDS (London, England) · 2008Trial
- Highly active antiretroviral therapy versus zidovudine/nevirapine effects on early breast milk HIV type-1 Rna: a phase II randomized clinical trial.Antiviral therapy · 2008Trial
- Early response to highly active antiretroviral therapy in HIV-1-infected Kenyan children.Journal of acquired immune deficiency syndromes (1999) · 2007Trial
- Breast milk HIV-1 suppression and decreased transmission: a randomized trial comparing HIVNET 012 nevirapine versus short-course zidovudine.AIDS (London, England) · 2005Trial
- Longitudinal analysis of human immunodeficiency virus type 1 RNA in breast milk and of its relationship to infant infection and maternal disease.The Journal of infectious diseases · 2003Trial
- Breast-milk infectivity in human immunodeficiency virus type 1-infected mothers.The Journal of infectious diseases · 2003Trial
- Clinical diagnostic value of targeted next generation sequencing for lower respiratory tract infection: a retrospective study.Frontiers in cellular and infection microbiology · 2026Article
- Human papillomavirus and abnormal cervical lesions among HIV-infected women in HIV-discordant couples from Kenya.Sexually transmitted infections · 2020Article
28 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 9 institutions in 3 countries.
Funding
Abstract
Accurate and sensitive quantification of human immunodeficiency virus type 1 (HIV-1) RNA has been invaluable as a marker for disease prognosis and for clinical monitoring of HIV-1 disease. The first generation of commercially available HIV-1 RNA tests were optimized to detect the predominant HIV-1 subtype found in North America and Europe, subtype B. However, these tests are frequently suboptimal in detecting HIV-1 genetic forms or subtypes found in other parts of the world. The goal of the present study was to evaluate the performance of a new viral load assay with non-subtype B viruses. A transcription-mediated amplification method for detection and quantitation of diverse HIV-1 subtypes, called the Gen-Probe HIV-1 viral load assay, is under development. In this study we examined the performance of the Gen-Probe HIV-1 viral load assay relative to that of the commonly used commercial HIV-1 RNA assays using a panel of primary isolates from Kenya. For comparison, we included several subtype B cloned viruses, and we quantified each virus using an in-house quantitative-competitive reverse transcriptase PCR (QC-RT-PCR) method and gag(p24) antigen capture. The Gen-Probe HIV-1 viral load assay and a version of the Roche AMPLICOR HIV-1 MONITOR test (version 1.5) that was designed to detect a broader range of subtypes were both sensitive for the quantification of Kenyan primary isolates, which represented subtype A, C, and D viruses. The Gen-Probe HIV-1 viral load assay was more sensitive for the majority of viruses than the Roche AMPLICOR HIV-1 MONITOR test version 1.0, the Bayer Quantiplex HIV RNA 3.0 assay, or a QC-RT-PCR method in use in our laboratory, suggesting that it provides a useful method for quantifying HIV-1 RNAs from diverse parts of the world, including Africa.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.